EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease

Laura K Massey, Jessica L Ward, Alexandra V Crooks, Emilie Guillot, Jose Ceron, Camilla Rubio, Victoria Convey, Melissa Tropf, Mei-Jyun Ciou, Jonathan P Mochel, Mark A Oyama

Journal of Veterinary Internal Medicine · 02.03.2026 · 40 (2)

DOI: 10.1093/jvimsj/aalag036 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 09.03.2026. Verfasst von Laura K Massey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania, 3900 Delancy St, Philadelphia, PA 191…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Dog Diseases, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ceva Santé Animal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose transport 2 inhibitors (SGLT2i) decrease morbidity and mortality in human patients with heart failure through a variety of proposed mechanisms, including natriuresis and glucosuria. The effects of SGLT2i on urine sodium (uNa) and urine glucose (uGlu) concentrations in dogs with heart disease have not been evaluated. Hypothesis/Objectives Administration of the SGLT2i dapagliflozin to dogs with heart disease will be well-tolerated and increase uNa and uGlu concentrations. Laboratory results and biomarker assays will provide insight into potential mechanisms of action. Animals Ten client-owned dogs with heart disease with or without congestive heart failure.

Methods

Prospective multicenter open-label uncontrolled study. Blood and urine biochemistry and oxidative and inflammatory biomarkers were evaluated at baseline and 5-7 days after 0.45-1 mg/kg/day PO dapagliflozin.

Results

A treatment effect was observed for uGlu (baseline, 14 mg/dL; IQR, 2-19 mg/dL; treatment effect +3102 mg/dL; IQR, 2390-4387 mg/dL; P = .002) but not for uNa (baseline, 75 mmol/L; IQR, 28-129 mmol/L; treatment effect, −41 mmol/L; IQR, −96-21 mmol/L; P = .12). Serum total thiol concentration increased (baseline, 145 μmol/L; SD, 32 μmol/L; treatment effect, +7 μmol/L; SD, 9 μmol/L; P = .04), suggesting an antioxidative effect. Serious adverse effects, including hypoglycemia or ketoacidosis, were not observed. Conclusions and clinical importance Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDog DiseasesSodium-Glucose Transporter 2 InhibitorsHeart DiseasesAnimalsDogsBiomarkersFemaleMaleSodiumProspective StudiesGlycosuriaHeart Failure

Stichwörter der Autor:innen

congestive heart failurediureticsglucosurianatriuresis

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesBiomarkersSodium-Glucose Transporter 2 InhibitorsSodium

Autor:innen und Institutionen

  • Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania, 3900 Delancy St, Philadelphia, PA 19104, United States.
  • Department of Veterinary Clinical Sciences, Lloyd Veterinary Medical Center College of Veterinary Medicine, Iowa State University, 1809 S. Riverside Dr, Ames, IA 50011, United States.
  • Ceva Santé Animale, 8 Rue de Logrono, Libourne 33500, France.
  • Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Campus Mare Nostrum, University of Murcia, Murcia 30100, Spain.
  • Precision One Health Initiative College of Veterinary Medicine, The University of Georgia, 501 D. W. Brooks Drive, Athens, GA, 30602, United States.

Förderung

  • Ceva Santé Animal

Zitieren

APA

Massey, L. K., Ward, J. L., Crooks, A. V., Guillot, E., Ceron, J., Rubio, C., Convey, V., Tropf, M., Ciou, M. J., Mochel, J. P., & Oyama, M. A. (2026). Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease. Journal of Veterinary Internal Medicine, 40(2). https://doi.org/10.1093/jvimsj/aalag036

Vancouver

Massey LK, Ward JL, Crooks AV, Guillot E, Ceron J, Rubio C, et al. Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease. Journal of Veterinary Internal Medicine. 2026;40(2). doi:10.1093/jvimsj/aalag036

BibTeX
@article{Massey2026,
  author = {Massey, Laura K and Ward, Jessica L and Crooks, Alexandra V and Guillot, Emilie and Ceron, Jose and Rubio, Camilla and Convey, Victoria and Tropf, Melissa and Ciou, Mei-Jyun and Mochel, Jonathan P and Oyama, Mark A},
  title = {Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {2},
  doi = {10.1093/jvimsj/aalag036}
}
Kostenlos starten →